Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-12-26
2006-12-26
Pak, John (Department: 1616)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S023000, C514S024000, C514S025000, C514S026000, C514S027000, C514S028000, C514S032000, C514S033000, C514S035000, C514S042000, C514S045000, C514S046000, C514S047000, C514S048000, C514S049000, C514S050000, C514S051000, C514S052000, C514S053000, C514S054000, C514S062000, C514S188000, C514S456000, C514S494000, C514S505000, C514S506000, C514S517000, C514S574000, C514S706000, C514S708000, C514S733000, C514S824000, C514S866000, C514S909000, C424S641000, C424S643000, C424S655000, C424S656000, C424S702000, C424S
Reexamination Certificate
active
07153877
ABSTRACT:
A method for preventing and or reducing the symptoms of insulin resistance and a related syndrome in persons comprises identifying persons having or at risk for having such symptoms, and administering to them an effective amount of a composition comprising niacin-bound chromium that prevents or reduces the symptoms. Compositions incorporating niacin-bound chromium and additional compounds also are disclosed that are particularly effective in synergistically preventing or reducing these symptoms.
REFERENCES:
patent: 3764692 (1973-10-01), Lowenstein
patent: 4923855 (1990-05-01), Jensen
patent: 4954492 (1990-09-01), Jensen
patent: 5116820 (1992-05-01), Hiji
patent: 5194615 (1993-03-01), Jensen
patent: 5266560 (1993-11-01), Furman et al.
patent: 5480657 (1996-01-01), Allen
patent: 5536516 (1996-07-01), Moffett et al.
patent: 5543405 (1996-08-01), Keown et al.
patent: 5567424 (1996-10-01), Hastings
patent: 5612039 (1997-03-01), Policappelli et al.
patent: 5626849 (1997-05-01), Hastings et al.
patent: 5656314 (1997-08-01), Moffett et al.
patent: 5716976 (1998-02-01), Bernstein
patent: 5783603 (1998-07-01), Majeed et al.
patent: 5905075 (1999-05-01), Harpe et al.
patent: 5911992 (1999-06-01), Braswell et al.
patent: 5981510 (1999-11-01), Fujiwara et al.
patent: 6034125 (2000-03-01), McLeod
patent: 6048846 (2000-04-01), Cochran
patent: 6100251 (2000-08-01), De la Harpe et al.
patent: 6160172 (2000-12-01), Balasubramanyam et al.
patent: 6203819 (2001-03-01), Fine
patent: 6207714 (2001-03-01), Clouatre et al.
patent: 6217898 (2001-04-01), Cavazza
patent: 6258848 (2001-07-01), Fantus
patent: 6291533 (2001-09-01), Fleischner
patent: 6352713 (2002-03-01), Kirschner et al.
patent: 6383482 (2002-05-01), Gorsek
patent: 6395296 (2002-05-01), Balasubramanyam et al.
patent: 6399089 (2002-06-01), Yegorova et al.
patent: 6413545 (2002-07-01), Alviar et al.
patent: 6420350 (2002-07-01), Fleischner
patent: 6441041 (2002-08-01), Clouatre et al.
patent: 6447807 (2002-09-01), Clouatre et al.
patent: 6476071 (2002-11-01), Clouatre et al.
patent: 6482858 (2002-11-01), Clouatre et al.
patent: 6541026 (2003-04-01), Siskind
patent: 6579866 (2003-06-01), McCleary
patent: 6589566 (2003-07-01), Ueda et al.
patent: 6638542 (2003-10-01), Nieuwenhuizen et al.
patent: 6809115 (2004-10-01), Katz et al.
patent: 6967030 (2005-11-01), Wright et al.
patent: 2001/0031744 (2001-10-01), Kosbab
patent: 2001/0044469 (2001-11-01), Clouatre et al.
patent: 2002/0132219 (2002-09-01), McCleary
patent: 2003/0119913 (2003-06-01), Ohia et al.
patent: 2003/0133992 (2003-07-01), Bagchi et al.
patent: 2003/0207942 (2003-11-01), Bhaskaran et al.
patent: 2003/0220329 (2003-11-01), Surwit et al.
patent: 2004/0014692 (2004-01-01), Bagchi et al.
patent: 2004/0157929 (2004-08-01), Ohia et al.
patent: 2004/0186181 (2004-09-01), Bagchi et al.
patent: 0 714 663 (1996-06-01), None
patent: 10262610 (1998-10-01), None
patent: WO 89/10357 (1989-11-01), None
patent: WO 98/28989 (1998-07-01), None
patent: WO 99/03464 (1999-01-01), None
patent: WO 00/12080 (2000-03-01), None
patent: WO 00/48983 (2000-08-01), None
patent: WO 00/57729 (2000-10-01), None
patent: WO 02/0788616 (2002-10-01), None
U.S. Appl. No. 60/554,653, filed Mar. 19, 2004, Bagchi et al.
U.S. Appl. No. 60/628,381, filed Nov. 16, 2004, Bagchi et al.
Separate systems for serotonin and leptin in appetite control, Jason CG Halford et al. The Finnish Medical Society Duodecim,Ann Med 2000; 32: 222-232.
Serotonin induces mapk activation in primary cultures of cortical neurons; L.M. Tolbert et al.Division of Molecular Psychiatry, Yale University, New Haven, CT, USA, date unavailable.
Effect of hydroxycitric acid on serotonin release from isolated rat brain cortex, by Sunny E. Ohia et al. Department of Pharmacy Sciences, School of Pharmacy and Allied Health Professions, Creighton University, Omaha, NE 68178, date unavailable.
(-)-Hydroxycitrates—The usefulness of (-)-hydroxycitric acid as an obesity regulator is attracting more attention from the food & pharmaceutical industry. Can it be called an ingredient for functional foods? By James Verghese; The World of Ingredients, date unavailable.
Enhancing central and peripheral insulin activity as a strategy for the treatment of endogenous depression—an adjuvant role for chromium picolinate? By M.F. McCarthy;Medical Hypotheses(1994) 43: 247-252.
The Diet and health benefits of HCA—How this all-natural diet aid promotes weight loss and inhibits fat production, By Dallas Clouatre, Ph.D. et al. A Keats Good Health Guide (1994).
AIM Metabolite (1999) AIM International, Inc.
Chromium, http://www.supplementdirect.com/research/chromium.html, pp. 1-13, date unavailable.
Anti-Fat Nutrients, by Dallas Clouatre, (1993) Ph.D. Fax Publishing, San Francisco, CA.
Encyclopedia of Nutritional Supplements, The Essential Guide for Improving your Health Naturally, by Michael T. Murray, N.D. (1996) Prima Publishing, Random House, Inc. New York. pp. 194-198.
Beware of New Weight Loss Products, by Pat Kendall, Ph.D., R.D. Food Science and Human Nutrition Specialist, Colorado State University Cooperative Extension Jul. 7, 1999.
Weight Loss—An alternative Medicine Definitive Guide, by Burton Goldberg; AlternativeMedicine.com Books, Tiburon, California, date unavailable.
Herbs and Weight Loss FAQ's; http://herbsforhealth.about.com/library, pp. 1-3, date unavailable.
Evaluating Natural Weight Loss Supplements, http://altmedicine.about.com/library/weekly; pp. 1-8, date unavailable.
Physiological Reviews—Chromium Occurence and Function in Biological Systems, by Walter Mertz, Division of Biochemistry, Walter Reed Army Institute of Research, Walter Reed Army Medical Center, Washington, D.C. The American Physiological Society, vol. 49, No. 2, Apr. 1969, pp. 163-239.
Influence of (-)-hydroxycitrate on lipigenesis in chickens and rat, by Chee H. Romsos, DR; http:www.ncbi.nlm.nih.gov, date unavailable.
Role of fatty acid synthesis in the control of insulin-stimulated glucose utilization by rat adipocytes, by Susan K. Fried, et al. Journal of Lipid Research, vol. 22, 1981, pp. 753-762.
Implications of steroid saponins and sapogenis in the hypocholesterolemic effect of fenugreek, by Yves Sauvalre et al. LIPIDS, vol. 26, No. 3 (1991).
Antidiabetic effects of S-allyl cysteine sufphoxide isolated from garlicAllium sativum Linn; Indian Journal of Experimental Biology, vol. 30, Jun. 1992, pp. 523-526.
More direct evidence for a malonyl-CoA-carnitine palmitoyltransferase I interaction as a key event in pancreatic beta-cell signaling, by S. Chen, et al. Diabetes, vol. 43, Issue 7, pp. 878-883, 1994.
Effects of chromium and guar on sugar-induced hypertension in rats, by H.G. Preuss et al.Clinical Nephrology, vol. 44, No. 3 (1995).
New Information on (-)-hydroxycitric acid/HCA, by Dallas Clouatre, Ph.D. Clouatre Consulting Group, Sep. 5, 1995.
Current Zinc Intake and Risk of Diabetes and Coronary Artery Disease and Factors Associated with Insulin Resistance in Rural and Urgan Populations of North India, by: Ram B. Singh, et al.Journal of the American College of Nutrition, vol. 17, No. 6, pp. 564-570 (1998).
Toward a wholly nutritional therapy for type 2 diabetes, by M.F. McCarty;Medical hypothesis, vol. 54, Issue 3, Mar. 2000, pp. 483-487.
Clinical Study on Ephedra-Free Super Citrimax® ; Interhealth, dated Jan. 29, 2004 Press Release.
Researchers Reveal the Beauty of Super CitriMax® —Again; New HCA Study Confirms Super CitriMax® may be the most Effective, All-Natural Diet Ingredient Yet, pp. 1-8, date unavailable.
The Diet and Health Benefits of HCA (Hydroxycitric Acid) How this all-natural diet aid promotes weight loss and inhibits fat production, by Dallas Clouatre, Ph.D. et al. A Good Health Guide, date unavailable.
Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment, by M.A. Heffernan, et al.International Journal of Obesity(2001) vol. 25, pp. 1442-1449.
Leptin increases serotonin turnover by inhibition of brain nitric oxide synthesis, by
Bagchi Debasis
Kothari Shil C.
Preuss Harry G.
Fliesler & Meyer LLP
Interhealth Nutraceuticals Incorporated
Pak John
LandOfFree
Method and composition for preventing or reducing the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method and composition for preventing or reducing the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method and composition for preventing or reducing the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3701992